Clinical Trial Update: Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials [Phase 3]

View source ↗

Summary

Phase 3 safety and antiviral activity update for Clevudine in Hepatitis B patients who completed L-FMAU-301 or L-FMAU-302; the trial has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Clevudine (clevudine)

Snippet

Sponsor: Bukwang Pharmaceutical | Conditions: Hepatitis B | Phase 3 | Status: TERMINATED